Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, June 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 107 articles:
HTML format


 

Single Articles

  1. DUDEK AM, van Kampen JGM, Witjes JA, Kiemeney LALM, et al
    LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer.
    Cancer Med. 2018 Jun 1. doi: 10.1002/cam4.1570.
    Abstract    

    Abstract available

  2. ROUANNE M, Roumiguie M, Houede N, Masson-Lecomte A, et al
    Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    World J Urol. 2018 Jun 1. pii: 10.1007/s00345-018-2332.
    Abstract    

    Abstract available

  3. JIN Z, Yao J, Xie N, Cai L, et al
    Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer.
    J Immunol Res. 2018;2018:5038172.
    Abstract    

    Abstract available

  4. VAN DER HEIJDEN AG, Mengual L, Ingelmo-Torres M, Lozano JJ, et al
    Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    Clin Epigenetics. 2018;10:71.
    Abstract    

    Abstract available

  5. ZHOU L, Wei E, Zhou B, Bi G, et al
    Anti-proliferative benefit of curcumol on human bladder cancer cells via inactivating EZH2 effector.
    Biomed Pharmacother. 2018;104:798-805.
    Abstract    

    Abstract available

  6. SHINDO T, Niinuma T, Nishiyama N, Shinkai N, et al
    Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer.
    Oncotarget. 2018;9:24457-24469.
    Abstract    

    Abstract available

  7. EBBING J, Heckmann RC, Collins JW, Miller K, et al
    Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer.
    Sci Rep. 2018;8:8360.
    Abstract    

    Abstract available

  8. HA HK, Koo PJ, Kim SJ
    Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis.
    Oncology. 2018;95:31-38.
    Abstract    

    Abstract available

  9. VAN OSCH FHM, Jochems SHJ, Reulen RC, Pirrie SJ, et al
    The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study.
    Cancer Causes Control. 2018 May 30. pii: 10.1007/s10552-018-1046.
    Abstract    

    Abstract available

  10. RAHMAT JN, Esuvaranathan K, Mahendran R
    Bacillus Calmette-Guerin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival.
    Oncol Lett. 2018;15:9231-9241.
    Abstract    

    Abstract available

  11. WANG Y, Liu J, Yang X, Liu Y, et al
    Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.
    Onco Targets Ther. 2018;11:2891-2899.
    Abstract    

    Abstract available

  12. ZIEGLER J, Ho J, Gibson IW, Nayak JG, et al
    Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer.
    Transpl Infect Dis. 2018 May 29:e12931. doi: 10.1111/tid.12931.
    Abstract    

    Abstract available

  13. JURACEK J, Stanik M, Peltanova B, Adamcova S, et al
    [Urinary MicroRNAs as Potential Biomarkers of Bladder Cancer].
    Klin Onkol. 2018;31.
    Abstract    

    Abstract available

  14. XU Y, Tong Y, Ying J, Lei Z, et al
    Chrysin induces cell growth arrest, apoptosis, and ER stress and inhibits the activation of STAT3 through the generation of ROS in bladder cancer cells.
    Oncol Lett. 2018;15:9117-9125.
    Abstract    

    Abstract available

  15. WANG JP, Leng JY, Zhang RK, Zhang L, et al
    Functional analysis of gene expression profiling-based prediction in bladder cancer.
    Oncol Lett. 2018;15:8417-8423.
    Abstract    

    Abstract available

  16. WAKAI K, Utsumi T, Yoneda K, Oka R, et al
    Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor.
    Int J Clin Oncol. 2018 May 26. pii: 10.1007/s10147-018-1299.
    Abstract    

    Abstract available

  17. ANDOLINO C, Hess C, Prince T, Williams H, et al
    Drug-induced keratin 9 interaction with Hsp70 in bladder cancer cells.
    Cell Stress Chaperones. 2018 May 25. pii: 10.1007/s12192-018-0913.
    Abstract    

    Abstract available

  18. MESSING EM, Tangen CM, Lerner SP, Sahasrabudhe DM, et al
    Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
    JAMA. 2018;319:1880-1888.
    Abstract    

    Abstract available

  19. KAFFENBERGER SD, Miller DC, Nielsen ME
    Simplifying Treatment and Reducing Recurrence for Patients With Early-Stage Bladder Cancer.
    JAMA. 2018;319:1864-1865.
    Abstract    



  20. BOLAT D, Celik S, Aydin ME, Aydogdu O, et al
    Assessment of the quality of life and sexual functions of patients followed-up for non-muscle invasive bladder cancer: preliminary results of the prospective-descriptive study.
    Turk J Urol. 2018 Mar 9:1-6. doi: 10.5152/tud.2018.30040.
    Abstract    

    Abstract available

  21. CHEN H, Li X, Broderick N, Liu Y, et al
    Identification and characterization of bladder cancer by low-resolution fiber-optic Raman spectroscopy.
    J Biophotonics. 2018 May 24:e201800016. doi: 10.1002/jbio.201800016.
    Abstract    

    Abstract available

  22. SHANG Z, Wang J, Wang X, Yan H, et al
    Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients.
    Cancer Manag Res. 2018;10:1177-1190.
    Abstract    

    Abstract available

  23. ASCHENBRENNER DS
    Bladder Cancer Drug Approved to Treat Stage III Non-Small Cell Lung Cancer.
    Am J Nurs. 2018;118:26-27.
    Abstract    



  24. BARTH I, Schneider U, Grimm T, Karl A, et al
    Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
    Virchows Arch. 2018;472:749-758.
    Abstract    

    Abstract available

  25. ROBINSON SP, Farooq A, Laniado M, Motiwala H, et al
    The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience.
    Int Braz J Urol. 2018;44:45-52.
    Abstract    

    Abstract available

  26. FAIREY AS, Mclarty R
    Orthotopic bladder substitution for bladder cancer patients undergoing radical cystectomy: A call to action.
    Can Urol Assoc J. 2018;12:187.
    Abstract    



  27. MEKAYTEN M, Yutkin V, Duvdevani M, Pode D, et al
    High frequency of bladder cancer after nephroureterectomy: justification for adjuvant intravesical treatment?
    Res Rep Urol. 2018;10:33-38.
    Abstract    

    Abstract available

  28. LI D, Hao X, Song Y
    An integrated analysis of key microRNAs, regulatory pathways and clinical relevance in bladder cancer.
    Onco Targets Ther. 2018;11:3075-3085.
    Abstract    

    Abstract available

  29. ZHU Y, Liang S, Pan H, Cheng Z, et al
    Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36.
    J Biosci. 2018;43:365-373.
    Abstract    

    Abstract available

  30. CHRISTODOULOU M, Reeves KJ, Hodgson C, Zeniou A, et al
    Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.
    Radiother Oncol. 2018 Jun 2. pii: S0167-8140(18)30281.
    Abstract    

    Abstract available

  31. WEBER L, Schulz WA, Philippou S, Eckardt J, et al
    Characterization of the Olfactory Receptor OR10H1 in Human Urinary Bladder Cancer.
    Front Physiol. 2018;9:456.
    Abstract    

    Abstract available

  32. JIANG S, Tian F, Wang Q, Cheng W, et al
    High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer.
    Cancer Biomark. 2018 May 25. pii: CBM181202. doi: 10.3233/CBM-181202.
    Abstract    

    Abstract available

  33. JUNG A, Nielsen ME, Crandell JL, Palmer MH, et al
    Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review.
    Cancer Nurs. 2018 Jun 1. doi: 10.1097/NCC.0000000000000606.
    Abstract    

    Abstract available

  34. RAJWA P, Zyczkowski M, Paradysz A, Bujak K, et al
    Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy.
    Eur Rev Med Pharmacol Sci. 2018;22:3027-3037.
    Abstract    

    Abstract available

  35. DONG ZC, Zhang D, Wang SB, Lin ZQ, et al
    Target inhibition on GSK-3beta by miR-9 to modulate proliferation and apoptosis of bladder cancer cells.
    Eur Rev Med Pharmacol Sci. 2018;22:3018-3026.
    Abstract    

    Abstract available

  36. WU SQ, Xu R, Li XF, Zhao XK, et al
    Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.
    Oncotarget. 2018;9:25294-25303.
    Abstract    

    Abstract available

  37. SNELL KIE, Ward DG, Gordon NS, Goldsmith JC, et al
    Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification.
    Oncotarget. 2018;9:25244-25253.
    Abstract    

    Abstract available

  38. AUDENET F, Farkas AM, Anastos H, Galsky MD, et al
    Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.
    World J Urol. 2018 Jun 2. pii: 10.1007/s00345-018-2359.
    Abstract    

    Abstract available

  39. YU Y, Cao H, Zhang M, Shi F, et al
    Prognostic value of DNA methylation for bladder cancer.
    Clin Chim Acta. 2018;484:207-212.
    Abstract    

    Abstract available

  40. YANG GL, Zhang LH, Liu Q, Wang ZL, et al
    Commentary on "A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience."
    Urol Oncol. 2018 May 30. pii: S1078-1439(18)30164.
    Abstract    

    Abstract available

  41. DANESHMAND S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, et al
    Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
    Urol Oncol. 2018 May 30. pii: S1078-1439(18)30135.
    Abstract    

    Abstract available

  42. HUANG CY, Lin YC, Shiue HS, Chen WJ, et al
    Comparison of Arsenic Methylation Capacity and Polymorphisms of Arsenic Methylation Genes between Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Toxicol Lett. 2018 May 30. pii: S0378-4274(18)30231.
    Abstract    

    Abstract available

  43. JIN H, Sun W, Zhang Y, Yan H, et al
    MicroRNA-411 Downregulation Enhances Tumor Growth by Upregulating MLLT11 Expression in Human Bladder Cancer.
    Mol Ther Nucleic Acids. 2018;11:312-322.
    Abstract    

    Abstract available

  44. DIAS LP, Luzo ACM, Volpe BB, Duran M, et al
    Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guerin (BCG) in non-muscle invasive bladder cancer.
    Tissue Cell. 2018;52:17-27.
    Abstract    

    Abstract available

  45. NAIK N, Lin M, Lin P
    Genitourinary involvement of lymphomas on FDG-PET.
    Br J Radiol. 2018;91:20170273.
    Abstract    

    Abstract available

  46. WHALEN KE, Eagle RC Jr, Vrabec TR
    CASE OF METASTATIC UROTHELIAL CARCINOMA OF THE RETINA AND VITREOUS.
    Retin Cases Brief Rep. 2018;12:177-180.
    Abstract    

    Abstract available

  47. TAN WS, Tan WP, Tan MY, Khetrapal P, et al
    Novel urinary biomarkers for the detection of bladder cancer: A systematic review.
    Cancer Treat Rev. 2018;69:39-52.
    Abstract    

    Abstract available

  48. RETZ M, Karl A
    [Bladder cancer : Current diagnosis and treatment modalities].
    Urologe A. 2018;57:655-656.
    Abstract    



  49. RASHIDIAN H, Zendehdel K, Daroudi R, Ebadzadeh MR, et al
    Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran.
    Iran J Public Health. 2018;47:567-574.
    Abstract    

    Abstract available

  50. RINALDETTI S, Rempel E, Worst TS, Eckstein M, et al
    Subclassification, survival prediction and drug target analyses of chemotherapy-naive muscle-invasive bladder cancer with a molecular screening.
    Oncotarget. 2018;9:25935-25945.
    Abstract    

    Abstract available

  51. SU G, He Q, Wang J
    Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review.
    Front Physiol. 2018;9:652.
    Abstract    

    Abstract available

  52. TOLLE A, Blobel CC, Jung K
    Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017.
    Biomark Med. 2018 Jun 13. doi: 10.2217/bmm-2017-0392.
    Abstract    

    Abstract available

  53. ZO RB, Long Z
    MiR-124-3p suppresses bladder cancer by targeting DNA methyltransferase 3B.
    J Cell Physiol. 2018 Jun 12. doi: 10.1002/jcp.26591.
    Abstract    

    Abstract available

  54. RAFIEMANESH H, Lotfi Z, Bakhtazad S, Ghoncheh M, et al
    The epidemiological and histological trend of bladder cancer in Iran.
    J Cancer Res Ther. 2018;14:532-536.
    Abstract    

    Abstract available

  55. YANG J, Li W, Zhang Z, Shen J, et al
    PSCArs2294008 T polymorphism increases the risk of bladder cancer in Bai, Dai, and Han ethnicity in China and a potential mechanism.
    Genes Genomics. 2018;40:531-541.
    Abstract    

    Abstract available

  56. MAZDAK H, Tolou-Ghamari Z
    Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran.
    Arab J Urol. 2018;16:206-210.
    Abstract    

    Abstract available

  57. CHEN Y, Li W, Zeng Z, Tang Y, et al
    (-)-Gochnatiolide B, synthesized from dehydrocostuslactone, exhibits potent anti-bladder cancer activity in vitro and in vivo.
    Sci Rep. 2018;8:8807.
    Abstract    

    Abstract available

  58. POIRION OB, Chaudhary K, Garmire LX
    Deep Learning data integration for better risk stratification models of bladder cancer.
    AMIA Jt Summits Transl Sci Proc. 2018;2017:197-206.
    Abstract    

    Abstract available

  59. HARIHARAN N, Ashcraft KA, Svatek RS, Livi CB, et al
    Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration.
    J Obes. 2018;2018:9247864.
    Abstract    

    Abstract available

  60. GOURD E
    EMA restricts use of anti-PD-1 drugs for bladder cancer.
    Lancet Oncol. 2018 Jun 7. pii: S1470-2045(18)30433.
    Abstract    



  61. WANG JF, Zhou XF, Fang DB, Wu ZM, et al
    [The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer].
    Zhonghua Yi Xue Za Zhi. 2018;98:1614-1616.
    Abstract    

    Abstract available

  62. BOSSCHIETER J, Hentschel A, Savci-Heijink CD, Patrick van der Voorn J, et al
    Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors.
    Clin Genitourin Cancer. 2018 May 11. pii: S1558-7673(18)30196.
    Abstract    

    Abstract available

  63. JENA R
    Bladder Cancer Virtual Special Issue.
    Clin Oncol (R Coll Radiol). 2018 Jun 5. pii: S0936-6555(18)30276.
    Abstract    



  64. VARTOLOMEI MD, Porav-Hodade D, Ferro M, Mathieu R, et al
    Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
    Urol Oncol. 2018 Jun 5. pii: S1078-1439(18)30166.
    Abstract    

    Abstract available

  65. LI Z, Lin C, Zhao L, Zhou L, et al
    Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer.
    Biomed Pharmacother. 2018;105:461-469.
    Abstract    

    Abstract available

  66. WEN H, Lee S, Zhu WG, Lee OJ, et al
    Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer.
    Biochim Biophys Acta. 2018 Jun 5. pii: S1388-1981(18)30126.
    Abstract    

    Abstract available

  67. WANG Z, Li H, Chi Q, Qiu Y, et al
    Clinical Significance of Serological and Urological Levels of Bladder Cancer-Specific Antigen-1 (BLCA-1) in Bladder Cancer.
    Med Sci Monit. 2018;24:3882-3887.
    Abstract    

    Abstract available

  68. FRANSEN VAN DE PUTTE EE, Otto W, Hartmann A, Bertz S, et al
    Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.
    Urol Oncol. 2018 Jun 4. pii: S1078-1439(18)30159.
    Abstract    

    Abstract available

  69. MARINONI F, Destro F, Selvaggio GGO, Riccipetitoni G, et al
    Urothelial carcinoma in children: A case series.
    Bull Cancer. 2018;105:556-561.
    Abstract    

    Abstract available

  70. HONKISZ SI, Naughton JF, Weng HY, Fourez LM, et al
    Evaluation of two-dimensional ultrasonography and computed tomography in the mapping and measuring of canine urinary bladder tumors.
    Vet J. 2018;232:23-26.
    Abstract    

    Abstract available

  71. HARTMAN R, Kawashima A
    Lower tract neoplasm: Update of imaging evaluation.
    Eur J Radiol. 2017 Nov 1. pii: S0720-048X(17)30415.
    Abstract    

    Abstract available

  72. KANEKO S, Li X
    X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism.
    Sci Adv. 2018;4:eaar5598.
    Abstract    

    Abstract available

  73. FANKHAUSER CD, Mostafid H
    Genetic polymorphisms may explain association between alcohol consumption and bladder cancer risk in East Asian men.
    Transl Androl Urol. 2018;7.
    Abstract    



  74. SANGUEDOLCE F, Cormio L
    The complex relationship between upper urinary tract and bladder cancer: clinical and predictive issues.
    Transl Androl Urol. 2018;7.
    Abstract    



  75. LIM C, Cohn JR, Cohn JA
    Can a diagnosis of bladder cancer motivate positive lifestyle changes-and prevent recurrent disease?
    Transl Androl Urol. 2018;7.
    Abstract    



  76. ZHANG L, Feng C, Zhou Y, Zhou Q, et al
    Dysregulated genes targeted by microRNAs and metabolic pathways in bladder cancer revealed by bioinformatics methods.
    Oncol Lett. 2018;15:9617-9624.
    Abstract    

    Abstract available

  77. CHEN Z, Zhou L, Liu X, Wang L, et al
    Loss of Fezf2 promotes malignant progression of bladder cancer by regulating the NF-kappaB signaling pathway.
    Lab Invest. 2018 Jun 20. pii: 10.1038/s41374-018-0077.
    Abstract    

    Abstract available

  78. CLINTON TN, Lotan Y
    The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer.
    Future Oncol. 2018 Jun 21. doi: 10.2217/fon-2018-0328.
    Abstract    

    Abstract available

  79. FITZPATRICK R, Baverstock R
    Muscle invasive bladder cancer presenting as recurrent autonomic dysreflexia - a wolf in wolf's clothing.
    J Spinal Cord Med. 2018 Jun 20:1-4. doi: 10.1080/10790268.2018.1487188.
    Abstract    

    Abstract available

  80. HE C, Zhang Q, Gu R, Lou Y, et al
    miR-96 regulates migration and invasion of bladder cancer through epithelial-mesenchymal transition in response to transforming growth factor-beta1.
    J Cell Biochem. 2018 Jun 19. doi: 10.1002/jcb.27172.
    Abstract    

    Abstract available

  81. LIN MG, Hong YK, Zhang Y, Lin BB, et al
    Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN.
    Eur Rev Med Pharmacol Sci. 2018;22:3370-3377.
    Abstract    

    Abstract available

  82. WANG Y, Li LJ, Qiu MX, Gong BS, et al
    Effects of paclitaxel combined with miR-448 on growth and proliferation of bladder cancer EJ cells.
    Eur Rev Med Pharmacol Sci. 2018;22:3363-3369.
    Abstract    

    Abstract available

  83. LICHTENEGGER E, Koll F, Haas H, Mantwill K, et al
    The oncolytic Adenovirus XVir-N-31 as a novel therapy in muscle-invasive bladder cancer.
    Hum Gene Ther. 2018 Jun 19. doi: 10.1089/hum.2018.
    Abstract    

    Abstract available

  84. ZHONG J, Switchenko J, Jegadeesh NK, Cassidy RJ, et al
    Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
    Am J Clin Oncol. 2018 Jun 16. doi: 10.1097/COC.0000000000000471.
    Abstract    

    Abstract available

  85. KOK VC, Zhang HW, Lin CT, Huang SC, et al
    Positive association between hypertension and urinary bladder cancer: epidemiologic evidence involving 79,236 propensity score-matched individuals.
    Ups J Med Sci. 2018 Jun 18:1-7. doi: 10.1080/03009734.2018.1473534.
    Abstract    

    Abstract available

  86. LIN WY, Wu CT, Chen MF, Chang YH, et al
    Cystectomy for bladder cancer in elderly patients is not associated with increased 30- and 90-day mortality or readmission, length of stay, and cost: propensity score matching using a population database.
    Cancer Manag Res. 2018;10:1413-1418.
    Abstract    

    Abstract available

  87. GHODOUSSIPOUR S, Daneshmand S
    Current controversies on the role of lymphadenectomy for bladder cancer.
    Urol Oncol. 2018 Jun 14. pii: S1078-1439(18)30157.
    Abstract    

    Abstract available

  88. LORAS A, Trassierra M, Sanjuan-Herraez D, Martinez-Bisbal MC, et al
    Bladder cancer recurrence surveillance by urine metabolomics analysis.
    Sci Rep. 2018;8:9172.
    Abstract    

    Abstract available

  89. WOOLBRIGHT BL, Choudhary D, Mikhalyuk A, Trammel C, et al
    The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
    Mol Cancer Ther. 2018 Jun 15. pii: 1535-7163.MCT-18-0063.
    Abstract    

    Abstract available

  90. THIEL T, Ryk C, Renstrom-Koskela L, Steineck G, et al
    Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    World J Urol. 2018 Jun 15. pii: 10.1007/s00345-018-2375.
    Abstract    

    Abstract available

  91. WU P, Zhang G, Zhao J, Chen J, et al
    Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China.
    Front Cell Infect Microbiol. 2018;8:167.
    Abstract    

    Abstract available

  92. IEMURA Y, Fukui S, Matsumura Y, Kagebayashi Y, et al
    [Bladder Rupture during Intravesical BCG Therapy : A Case Report].
    Hinyokika Kiyo. 2018;64:25-28.
    Abstract    

    Abstract available

  93. KULAC I, Arslankoz S, Netto GJ, Ertoy Baydar D, et al
    Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
    Virchows Arch. 2018;472:969-974.
    Abstract    

    Abstract available

  94. NORTH D, Jaw J, Hill P, Bateman S, et al
    Nephrogenic Adenoma Complicating Renal Transplantation: A Case Report and Discussion.
    Transplant Proc. 2017;49:2381-2383.
    Abstract    

    Abstract available

  95. MOURMOURAS N, Philippou A, Christopoulos P, Kostoglou K, et al
    Differential Expression of IGF-I Transcripts in Bladder Cancer.
    Anticancer Res. 2018;38:3453-3459.
    Abstract    

    Abstract available

  96. POSFAI B, Kuthi L, Varga L, Laczo I, et al
    The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
    Anticancer Res. 2018;38:3243-3254.
    Abstract    

    Abstract available

  97. MARI A, Kimura S, Foerster B, Abufaraj M, et al
    A Systematic Review and Meta-Analysis of the impact of Lymphovascular Invasion in Bladder Cancer Transurethral Resection Specimens.
    BJU Int. 2018 May 28. doi: 10.1111/bju.14417.
    Abstract    

    Abstract available

  98. EREDICS K, Bretterbauer KM, Comploj E, Friedl A, et al
    Bladder cancer in nonagenarians:a multicenter study of 123 patients.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14419.
    Abstract    

    Abstract available

  99. SUGITA S, Enokida H, Yoshino H, Miyamoto K, et al
    HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
    Int J Oncol. 2018 Jun 11. doi: 10.3892/ijo.2018.4435.
    Abstract    

    Abstract available

  100. ZHANG L, Yang G, Zhang R, Dong L, et al
    Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.
    Int J Oncol. 2018 May 30. doi: 10.3892/ijo.2018.4423.
    Abstract    

    Abstract available

  101. AUDENET F, Waingankar N, Ferket BS, Niglio SA, et al
    Effectiveness of transurethral resection (TUR) plus systemic chemotherapy as definitive treatment for muscle-invasive bladder cancer (MIBC) in population-level data.
    J Urol. 2018 Jun 4. pii: S0022-5347(18)43313-7. doi: 10.1016/j.juro.2018.
    Abstract    

    Abstract available

  102. DOWNS TM, Weissert JA, Ravvaz K
    Can we improve non-muscle-invasive bladder cancer (NMIBC) guideline adherence with smarter risk-stratification?
    J Urol. 2018 Jun 12. pii: S0022-5347(18)43357-5. doi: 10.1016/j.juro.2018.
    Abstract    



  103. KWON WA, Joung JY, Lim J, Oh CM, et al
    Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea.
    BMC Cancer. 2018;18:617.
    Abstract    

    Abstract available

  104. XIE H, Zhu Y, Zhang J, Liu Z, et al
    B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    BMC Cancer. 2018;18:590.
    Abstract    

    Abstract available

  105. LIU Y, Wang H, Zhong J, Wu C, et al
    Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis.
    BMC Cancer. 2018;18:642.
    Abstract    

    Abstract available

  106. LIU H, He W, Wang B, Xu K, et al
    MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    BMC Cancer. 2018;18:659.
    Abstract    

    Abstract available

  107. XIA Y, Liu Z, Yu W, Zhou S, et al
    The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
    PLoS One. 2018;13:e0198602.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;